{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:00:21Z","timestamp":1785409221957,"version":"3.56.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina de Familia. SEMERGEN"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.semerg.2025.102667","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T13:29:39Z","timestamp":1767878979000},"page":"102667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["SGLT2i compared to other non-insulin antidiabetics in Primary Care patients with earlier diabetes. Cohort profile and sample characteristics of DIAB-CV-AP study"],"prefix":"10.1016","volume":"52","author":[{"given":"J.","family":"Pablo-Ortega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Rey-Aldana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Segura-Fragoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Maz\u00f3n-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Portela-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"Gonz\u00e1lez-Juanatey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cinza-Sanjurjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semerg.2025.102667_bib0130","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global Burden of Cardiovascular Diseases and Risk Factors, 1990\u20132019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semerg.2025.102667_bib0135","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.jacc.2022.11.001","article-title":"Global burden of cardiovascular diseases and risks, 1990\u20132021","volume":"80","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semerg.2025.102667_bib0140","series-title":"Estad\u00edstica de Defunciones seg\u00fan la Causa de Muerte. A\u00f1o 2024","year":"2025"},{"key":"10.1016\/j.semerg.2025.102667_bib0145","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semerg.2025.102667_bib0150","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.semerg.2025.102667_bib0155","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2025.102667_bib0160","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2025.102667_bib0165","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2025.102667_bib0170","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2025.102667_bib0175","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2025.102667_bib0180","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2025.102667_bib0185","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2025.102667_bib0190","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semerg.2025.102667_bib0195","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"issue":"Suppl. 1","key":"10.1016\/j.semerg.2025.102667_bib0200","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.semerg.2025.102667_bib0205","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study","volume":"8","author":"Heerspink","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semerg.2025.102667_bib0210","doi-asserted-by":"crossref","first-page":"101418","DOI":"10.1016\/j.diabet.2022.101418","article-title":"Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study","volume":"49","author":"Karasik","year":"2023","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.semerg.2025.102667_bib0215","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/pds.5006","article-title":"Base de Datos para la Investigaci\u00f3n Farmacoepidemiol\u00f3gica en Atenci\u00f3n Primaria (BIFAP): a data resource for pharmacoepidemiology in Spain","volume":"29","author":"Maci\u00e1-Mart\u00ednez","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.semerg.2025.102667_bib0220","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","article-title":"Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.semerg.2025.102667_bib0225","doi-asserted-by":"crossref","first-page":"e00140","DOI":"10.1002\/edm2.103","article-title":"The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: design and exposure accrual for an evaluation of empagliflozin in routine clinical care","volume":"3","author":"Patorno","year":"2020","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.semerg.2025.102667_bib0230","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/dom.13738","article-title":"Eligibility of patients with type 2 diabetes for sodium-glucose co-transporter-2 inhibitor cardiovascular outcomes trials: an assessment using the Diabetes Collaborative Registry","volume":"21","author":"Wittbrodt","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.semerg.2025.102667_bib0235","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/dom.13612","article-title":"How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study","volume":"21","author":"Birkeland","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.semerg.2025.102667_bib0240","first-page":"14","article-title":"Comparison of baseline clinical characteristics among people with type 2 diabetes on second-line therapy previously added with dapagliflozin or another oral glucose-lowering drug: AGORA study","volume":"36","author":"Pallar\u00e9s-Carratal\u00e1","year":"2024","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.semerg.2025.102667_bib0245","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.semerg.2020.06.027","article-title":"Factores asociados al riesgo cardiovascular y enfermedad cardiovascular y renal en el estudio IBERICAN (Identificaci\u00f3n de la poBlaci\u00f3n Espa\u00f1ola de RIesgo CArdiovascular y reNal): resultados definitivos","volume":"46","author":"Cinza-Sanjurjo","year":"2020","journal-title":"Med Fam SEMERGEN"},{"key":"10.1016\/j.semerg.2025.102667_bib0250","doi-asserted-by":"crossref","first-page":"679124","DOI":"10.3389\/fcvm.2021.679124","article-title":"Does combination therapy with SGLT2 inhibitors and renin\u2013angiotensin system blockers lead to greater reduction in cardiorenal events among patients with type 2 diabetes?","volume":"8","author":"Zhao","year":"2021","journal-title":"Front Cardiovasc Med"}],"container-title":["Medicina de Familia. SEMERGEN"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359325002205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359325002205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T15:55:28Z","timestamp":1769702128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1138359325002205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1138359325002205"],"URL":"https:\/\/doi.org\/10.1016\/j.semerg.2025.102667","relation":{},"ISSN":["1138-3593"],"issn-type":[{"value":"1138-3593","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2i compared to other non-insulin antidiabetics in Primary Care patients with earlier diabetes. Cohort profile and sample characteristics of DIAB-CV-AP study","name":"articletitle","label":"Article Title"},{"value":"Medicina de Familia. SEMERGEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semerg.2025.102667","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de M\u00e9dicos de Atenci\u00f3n Primaria (SEMERGEN). Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102667"}}